2012 EFNS 不宁腿综合征治疗指南
European guidelines on management of restless legs syndrome
2012-11-01
Final level A recommendations 最终A级推荐1、Strong recommendations 强推荐Rotigotine transdermal patch (1–3 mg) is effective for the short- and long-term treatment of primary RLS. 罗替戈汀透皮贴剂（1-3mg）短期和长期治疗原发性RLS有效。Ropinirole is effective of improving symptoms inprimary RLS when given at a mean dose of between 2.1 and 3.1 mg/day over the short-term.罗匹尼罗短期使用，平均日剂量为2.1-3.1mg时对于改善原发性RLS症状有效。Pramipexole is considered effective in the short-term at doses between 0.25 and 0.75 mg. 普拉克索短期治疗，剂量在0.25-0.75mg之间有效。Gabapentin enacarbil (1200 mg daily) is effective or the short-term treatment of primary RLS. 加巴喷丁缓释片（1200mg/d)短期治疗原发性RLS有效。Pregabalin (150 –450 mg daily) is effective for the short-term treatment of primary RLS.普瑞巴林（150-450mg/d）短期治疗原发性RLS有效。Gabapentin is effective for the short-term treatmentof primary RLS.加巴喷丁短期治疗原发性RLS有效。2、Weak recommendations 弱推荐There is high-quality evidence that shows that cabergoline (0.5– 3 mg/day) improves RLS symptoms; however, cabergoline cannot be recommendedbecause of serious adverse risks. 一项高质量证据表明卡麦角林（0.5– 3 mg/d）改善RLS症状；但由于其严重的不良反应，并不推荐其使用。There is high-quality evidence that shows that levodopa (up to 300 mg/day) improves RLS symptoms.However, given the higher risk of augmentation compared to dopamine agonists, levodopa should not be given at a dosage higher than 200 mg/day. In clinical practice, levodopa is now better established as a diagnostic test for RLS and as on demand treatment in sporadic RLS. Consequently the task force can only make a low recommendation for levodopa. 一项高质量证据表明左旋多（300mg/d）可改善RLS症状。但相比于多巴胺受体激动剂，考虑到增加剂量的风险，左旋多巴的剂量不应超过200mg/d。在临床实践中，左旋多巴目前最好是作为RLS的诊断性试验治疗和特发性RLS的需求治疗。因此，对左旋多巴只做低级别的推荐。
